medigraphic.com
ISSN 0016-3813 (Print)

2006, Number 6

<< Back Next >>

Gac Med Mex 2006; 142 (6)

Neuroendocrine differentiation and makers of cell proliferation in a group of patients with prostate adenocarcinoma and normal high serum prostate-specific antigen levels.

Guillermo Feria-Bernal, Víctor Manuel García-González, Figueroa-Granados V, Martínez-Benítez B, Uribe-Uribe NO

Language: Spanish
References: 21
Page: 441-446
PDF size: 528.44 Kb.


ABSTRACT

Objective. Study the morphologic characteristics of neuroendocrine cells in prostate cancer with normal versus elevated prostate specific antigen (PSA).
Materials and Methods. 372 cases of prostate cancer were identified during a 13 year period, of which 19 displayed normal PSA (group I). Sixteen controls with elevated PSA and similar histopathological characteristics (group II) were included. We studied the degree of tumor necrosis, vascular and perineural invasion. Synaptophysin (SP), neuron specific enolase (NSE), PSA, Ki-67 and p53 inmunoreactivity were also analyzed.
Results. Group I positive findings were 61% PSA, 28.6% SP, 7.1% NSE, 50% p53, and 78.6% Ki-67. Group II positive findings were 93% PSA, 13.3% SP, 26.6% NSE 46.6% p53, and 66.7% Ki-67. When we used a ‹80% cutoff point for PSA immunoreactivity in tumor cells , 69.2% of group I and 21.4% of group II were found.
Conclusions. The sole histopathological finding that showed statistical significance was the tissular expression of the specific prostatic antigen in 80% of neoplasic cells in group I. The increase of neuroendocrine cells was associated with a smaller number of tissular antigen producing cells, a finding that could be more apparent if we were to study a larger sample size.


REFERENCES

  1. Aihara, M, Scardino P, Truong T, Wheeler T, Goad J, Yang G, et al. The frequency of apoptosis correlates with the prognosis of Gleason Garde

  2. 3 adenocarcinoma of the prostate. Cancer 1995;75(2):522-529.

  3. Becker C, Piironen T, Pettersson K, Björk T, Wojno K, Oesterling J, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000;163:311-316.

  4. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88(11):2590-2597.

  5. Cherry J, Mordente J, Chapman J, Choudhury M, Tazaki H, Mallouh C, et al. Analysis of Cathepsin D forms and their clinical implications in human prostate cancer. J Urol 1998;160(6):2223-2228.

  6. Bostwick D, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh E, et al. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002;168:1204-1211.

  7. Burchardt T, Burchardt M, Chen MW, Cao Y, De la Taille A, Shabsigh a, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805.

  8. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch M and Gasser T. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998;160(2):406-410.

  9. Dénes F, Brito A, Dos-Santos A. Subcutaneous and testicular metastasis from prostatic adenocarcinoma with neuroendocrine differentiation. Braz J Urol 2001;27(1):52-54.

  10. di Sant’Agnese PA. Divergent neuroendocrine differentiation in prostatic carcinoma. Semin Diagn Pathol 2000;17(2):149-161.

  11. Gohji K, Kitazawa S, Tamada H, Katsuoka Y and Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165:1033-1036.

  12. Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen T, Määttänen L, et al. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001;165:1569-1574.

  13. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N and Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002(2);167:512-515.

  14. Kadmon D. Beyond prostate specific antigen – Markers for prostate cancer for the 21st century. J Urol 2000;163:828.

  15. Karazanashvili G and Per-Anders Abrahamsson. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003;169:445-457.

  16. Lehrer S, Diamond E, Stone N, Droller M and Stock R. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol 2002;168:2431-2433.

  17. Wehbi NK, Dugger A, Bonner R, Pitha J, Hurst R and Hemstreet G III. Pan-Cadherin as a high level phenotypic biomarker for prostate cancer. J Urol 2002;167:2215-2221.

  18. Yashi M, Muraishi O, Tokue A. Prostatic small-cell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide. BJU Int 2001;88(3):306-308.

  19. Yang, G, Stapleton A, Wheeler T, Truog L, Timmer T, Scaedino P, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Research 1996;2:399-401.

  20. Epstein J. Pathology of Prostatic Neoplasia. In: Campbell´s Urology, 8ed.. Edited by P. C. Walsh, A.B. Retik, E.D. Vaughan and A.J. Wein. Philadelphia: W.B. Saunders Co., vol. 4, capt 86, pp. 3025-3037, 2002.

  21. Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000;163:1739-1742.




2020     |     www.medigraphic.com